Men's Health Daily Brief
FDA approves first hepcidin-mimicking treatment for polycythemia vera: what patients should know
The FDA approved Mimrylo (rusfertide) for certain adults with polycythemia vera after a phase 3 trial showed fewer patients met criteria for phlebotomy. Here is what the approval does—and does not—mean.
What the FDA approved on August 28
The U.S. Food and Drug Administration approved Mimrylo (rusfertide) for adults with polycythemia vera whose disease has not been adequately controlled with existing therapies. Polycythemia vera causes the body to make too many red blood cells, which can thicken the blood and raise the risk of clots, stroke and heart attack. The approval is relevant to adults of every sex; NOCTI is covering it in the men’s health brief because recognizing blood-health symptoms and asking informed treatment questions matters across its adult audience.
How the new treatment works
Rusfertide is the first FDA-approved polycythemia vera treatment designed to mimic hepcidin, a hormone that helps regulate iron. By limiting the iron available for production of new red blood cells, the medicine is intended to help control red-cell overproduction. It is given as a weekly injection under the skin and is added to a patient’s ongoing care. This mechanism is not a reason to change iron intake, donate blood or alter prescribed treatment without guidance from the hematology team managing the disease.
What the phase 3 trial found
The FDA based the approval on the randomized, double-blind, placebo-controlled VERIFY study of 293 adults who still needed frequent phlebotomies despite standard care. FDA reported that 76.9% of participants receiving rusfertide did not require phlebotomy, compared with 32.9% receiving placebo; the trial registry defines the primary response window as weeks 20 through 32. The most common adverse reactions were injection-site reactions and anemia. ClinicalTrials.gov says the study continues with an open-label phase and follow-up, with overall completion estimated for 2027.
What the result does not establish
The approval does not mean rusfertide is appropriate for everyone with a high red-blood-cell count or for every person already diagnosed with polycythemia vera. The VERIFY participants had a specific diagnosis and a history of frequent phlebotomy despite ongoing therapy. A high hematocrit can have different causes, and a clinician uses blood tests and other evaluation to diagnose polycythemia vera. Trial percentages describe groups in a controlled study; they cannot predict an individual patient’s response.
Symptoms and when to seek medical care
The National Cancer Institute notes that polycythemia vera may be found on a routine blood test before symptoms appear. Possible symptoms include headache, dizziness, weakness, vision changes, itching—especially after warm or hot water—and a feeling of pressure or fullness below the ribs on the left side. Those symptoms can also have other causes, so they require clinical evaluation rather than self-diagnosis. Call 911 for signs of a stroke or heart attack, sudden chest pain, severe shortness of breath or another medical emergency.
Questions for an established care team
A person already being treated for polycythemia vera can ask whether the new approval fits their specific diagnosis, treatment history and phlebotomy needs; how weekly injections would interact with current therapy; what monitoring is required; and how anemia or injection-site reactions would be managed. Do not stop phlebotomy, aspirin, hydroxyurea, interferon, ruxolitinib or another prescribed therapy based on a news article. Treatment decisions belong with the qualified clinician who knows the patient’s medical record.
NOCTI’s wellness boundary
NOCTI helps adults discover independent massage and wellness providers; it does not diagnose blood disorders, prescribe medicine or verify eligibility for a treatment. Massage, stretching, hydration products and other recovery services do not treat polycythemia vera and do not replace hematology care. If you have a diagnosed clotting or blood condition, share the information a qualified wellness provider needs and obtain medical guidance before a service when your care team recommends it.
Sources
Find men's massage near you
Compare local providers privately and contact the professional you choose directly.
Search NOCTI